마크로젠 로고

• 12. Macrogen Recieves 'AA' ESG Rating from SUSTINVEST

• 04. Achieved 'ISMS-P(Personal Information & Information Security Management System)' Certification
• 03. Macrogen’s Covid-19 antibody fast-test kit gets CE-IVD certification
• 03. Macrogen to commercialize PRS-based disease predicting service
• 02. Macrogen secured the overseas business rights for the ImmuneMed COVID-19 kit
• 02. Macrogen, Lifex Biolabs to research Parkinson’s treatment

• 11. Launched gut health care program based on microbiological analysis program 'CellBiome' with Cellbiotech
• 10. Macrogen, Theragen Bio and DNA Link picked for K-DNA Big Data Pilot Business
• 10. Signed MOU with Avatamed, for personalized precision medicine services in cancer treatment
• 09. Macrogen, K-Quarantine System "Smart Mobile Lab" Exported to Indonesia
• 08. Obtained Europe's CE-IVD Certificate for COVID-19 test kit 'Axen™ COVID-19 RT'
• 08. Launched genetic health care subscription service ‘care8 DNA’ with SK Telecom and Invites Healthcare
• 06. Signed MOU with Anewheal for Personalized Healthcare Service
• 06. Achieved 'ISO/IEC 27001:2013' Certification
• 05. Obtained export approval for COVID-19 test kit 'Axen™ COVID-19 RT' from the Ministry of Food and Drug Safety (MFDS)
• 04. Signed MOU with Sungkyunkwan University for Forensic science Research and Development
• 02. Granted Korea patent for Cancer stem cell-specific biomakrers (Title: Cancer Stem Cell-Specific Biomarkers)
• 02. Announced Virus Isolation from the First Patient with SARS-CoV-2 in Korea in Journal of Korean Medical Science
• 02. Won "The Ministry of Employment and Labor Award" of Newsis 2020 Korea The Best Korea Job Company

• 12. 'Macrogen Research Outcome from ‘GenomeAsia 100K’ consortium Covered in Nature
• 12. Signed a MOU with global company 'ThermoFisher Scientific'
• 12. 'Signed License and Supply Agreement with Thermo Fisher Scientific
• 10. Granted Korea patent for Fusion protein comprising AXL and composition for diagnosing cancer
• 10. Announced one of the largest Northeast Asian Reference Database(NARD) in Genome Medicine
• 09. Granted U.S. patent for Blockchain data-sharing technology (Title: Data-sharing method based on the plurality of blockchains)
• 07. Selected as “2019 KOSDAQ Rising Star” for six consecutive years by the Korea Exchange
• 07. Selected as "2019 Korea Job Leading Company" by the Ministry of Employment and Labor
• 06. Signed a subscription agreement with microbiome analysis company, Microba
• 05. Designated as a “GCLP(Good Clinical Laboratory Practice)” facility by the KFDA
• 04. Released “MICROBE & ME,” a personal genome analysis service for gut microbiome screening test
• 04. Signed a MOU with Exosome Plus for "Jointly develop Exosome-based diagnostic and treatment solutions"
• 03. Signed a MOU with Australian microbial company 'Microba'
• 02. Received the certification of the NGS-based in vitro diagnostic reagent GMP (Good Manufacturing Practice)

• 11. Seoul HQ and Bundang PMC received CLIA Accreditation
• 09. Granted Korean patent for Blockchain data-sharing technology (Title: Data-sharing method based on the plurality of blockchains)
• 08. Seoul HQ and Bundang PMC received CAP Accreditation
• 07. Granted Korean patent for Blockchain Technology (Title: Bio-Information Data providing method, bio-information data storing method and bio-information data transferring system based on multiple blockchains)
• 06. Won "The Best Transparent Management Award" of the 10th Korea KOSDAQ Award from KOSDAQCA (KOSDAQ Listed Companies Association)
• 05. Selected as “2018 KOSDAQ Rising Star” for five consecutive years by the Korea Exchange
• 03. Established Macrogen Asia Pacific Pte. Ltd. (Singapore)
• 03. Acquired a license to CRISPR-Cas9 gene editing technology from Broad Institute of MIT and Harvard in the USA
• 01. Signed an agreement with Soonchunhyang University for "Joint research for healthcare innovation through precision medicine based on medical and genetic information"
• 01. Signed a technology transfer contract with Seoul National University Hospital for "Drug-induced gene scissors recombination vector"

• 12. Won Minister of Commerce, Industry and Energy Citation for Exporters of World’s Best Products on the 54th Export Day
• 12. Chosen as a “2017 Best Labor-Management Culture Company” by the Ministry of Employment and Labor
• 10. Obtained Personal Information Management System (PIMS) certification for the first time in the genome analysis industry
• 10. Signed a business agreement with the Myongji Medical Foundation for business cooperation and joint research for clinical adaptation of disease control protocol based on genome information
• 10. Macrogen USA received CAP Accreditation
• 09. Signed a business agreement with Knotus for non-clinical model animals for new drug evaluation
• 09. Established Macrogen Europe B.V.
• 07. Released "My Genomestory™," a personal genome analysis service
• 06. Signed a three-party business agreement with the Korea Certified Welfare Consultant Association and Joy Hospital for a disease prediction personal genome analysis service Jun declared “Vision for the next 20 years” to celebrate 20th anniversary of the founding
• 05. Selected as a “KOSDAQ Rising Star” by the Korea Exchange for the fourth year in a row
• 05. Signed a business agreement with the Korea Association of Health Promotion for the establishment of disease prediction big data
• 04. Obtained KFDA NGS Clinical Laboratory certification
• 03. Recognized as a KOLAS International Authorized Test Institution (ISO/IEC 17025, forensic genetics area)
• 03. Introduction of Illumina NovaSeq 6000 system

• 12. Obtained ‘Family-Friendly Company certification from the Ministry of Gender Equality and Family
• 12. Established MiGenstory, a joint corporation with Macrogen and LG Household & Health Care
• 12. Won 2016 World’s Best Product award from the Ministry of Commerce, Industry and Energy
• 12. Won 30 Million Dollar Export Tower award on the 53rd Export Day
• 12. Recognized as DAkkS International Authorized Test Institution (ISO/IEC 17025, Forensic genetics area)
• 12. Established Macrogen Spain branch (Madrid, Spain)
• 07. Signed an agreement with Chilgok Kyeongbuk University Hospital for joint research on precision medicine based on genome analysis for cancer patients and patients with intractable diseases
• 07. Signed an agreement with Chilgok Kyeongbuk University Hospital for joint research on precision medicine based on genome analysis for cancer patients and patients with intractable diseases
• 06. Chosen as one of the “300 World-Class Companies” by the Ministry of Commerce, Industry and Energy and the Small and Medium Business Administration
• 05. Signed an agreement with the National Cancer Center for joint research on precision medicine based on genome analysis for cancer patients
• 05. Selected as a ”2016 KOSDAQ Rising Star” by the Korea Exchange
• 05. Launched Non-Invasive Prenetal Test 'famplan' and New Born Screening Service 'ABOOBA'
• 04. Signed an agreement with the National Cancer Center for joint research on precision medicine based on genome analysis for cancer patients
• 03. Signed an agreement with Korea University Anam Hospital for joint research to realize precision medicine based on genome information
• 02. Participated in the Genome Asia 100K Project

• 12. Won Minister of Employment and Labor Government Citation for Contribution to Job Creation
• 12. Won 20 Million Dollar Export Tower award on the 52nd Export Day
• 12. Merged MCL (Macrogen corporation in the United States) and Axeq Technologies, Inc
• 11. Won Minister of Commerce, Industry and Energy Citation for Contribution to Global Specialist Company Fostering Program
• 09. Selected as an institution to host the development of a Korean foundation medicine model for personalized anti-cancer treatment supported by the Ministry of Industry and Commerce
• 07. Selected as an institution to host the development of a Korean foundation medicine model for personalized anti-cancer treatment supported by the Ministry of Industry and Commerce
• 05. Selected as a “2015 KOSDAQ Rising Star” by the Korea Exchange
• 04. Introduced new CI and slogan

• 12. Affiliate MG Med listed on the Korea New Exchange
• 12. Won “Best Company to Work For” award from the Small and Medium Business Administration and Ministry of Employment and Labor
• 07. Macrogen and ToolGen signed “Transformed Mouse Project”
• 07. Macrogen, EONE Laboratories and EONE Diagnomics Genome Center signed agreement on molecular diagnosis and genome analysis project
• 05. Selected as a “2014 KOSDAQ Hidden Champion” by the Korea Exchange
• 05. Chosen as Global Specialist Candidate by the Ministry of Industry and Commerce

• 12. Won presidential citation for contribution to promotion of venture companies in the Korea Venture-Startup Expo
• 11. Expansion and upgrade of high-tech SPF mouse facilities
• 07. Macrogen Corp. obtained Clinical Laboratory Improvement Amendments (CLIA) certification, the standard for laboratories in the United States.
• 06. Chosen as an institution to lead the fusion Advanced Technology Center (ATC) technology development project by the Ministry of Commerce, Industry and Energy
• 01. Chosen as “2012 Second-Half Best Contributor to Job Creation” by the Seoul Metropolitan Government

• 12. Established U.S. affiliate Macrogen Clinical Laboratory (MCL)
• 09. Obtained certification as Best Institution for Human Resources Development (joint certification from the Ministry of Employment and Labor, Ministry of Education, Science and Technology, Ministry of Knowledge Economy and Small and Medium Business Administration)
• 05. Started ‘joint development of personalized lung cancer medicine with Oscotec
• 02. Signed business agreement for joint entry into China’s diagnosis market with Ahn-Gook Pharm
• 01. Received CE certification for Macrogen BAC chip H1440 for the diagnosis of chromosome aberrations

• 07. Won 10 Million Dollar Export Tower award on the 48th Export Day
• 02. Launched Axeq, a global premium sequencing service brand
• 01. Obtained ISO13485:2003 certification for in-vitro diagnosis device

• 07. Signed a business agreement with LG Life Sciences for R&D and market entrance with “personalized treatment based on personal genome information”
• 03. Launched the “Asian Genome Road Project” with the Genomic Medicine Institute at Seoul National University and the Chosun Ilbo
• 02. Disclosed “Genome analysis of 10 Koreans and Establishment of Korean Standard Genome” with the Genomic Medicine Institute at Seoul National University

• 07. Selected as a participant in the biosimilar area in the New Growth Engine Smart Project” executed by the Ministry of Knowledge Economy
• 07. Signed an agreement for the promotion of genome analysis service and personalized medicine with Boryung Pharmaceutical

• 07. Won the 2008 Korea Health Industry Grand Prize in the bio venture area
• 06. Established Macrogen Europe branch (Amsterdam, Netherlands)
• 02. Established Macrogen Daejeon branch

• 11. Established Macrogen Japan Corp.
• 06. Established Soma Therapeutics, an affiliate for molecular diagnosis and new drug development by discovering disease genes

• 12. Macrogen back chip H1440 for the diagnosis of chromosome aberrations won excellence award in the Good Technology Competition of the Health Industry Technology Exhibition
• 10. Affiliate MG Med merged with NeoGenetic Co., Ltd, a gene diagnosis company
• 08. Signed joint R&D contract for commercialization of the Zymomonas strain for the commercialization of ethanol for fuel with Changhae Ethanol Co., Ltd
• 07. Merged with Vector Core A Co., Ltd, biotechnology company for vector development
• 03. Sale of CGH DNA chip for the diagnosis of chromosome aberrations approved by the Korea Food and Drug Administration (KFDA)

• 12. Established Macrogen Corp.
• 11. Received ISO9001 certification in all areas of the gene business
• 11. Established partnership with Applied Biosystems in the United States for a “DNA chip project”
• 10. Established Macrogen Young Scientist award for Biochemistry and Molecular Biology
• 01. Relocated the headquarters to the World Meridian Venture Center in Gasan-dong, Seoul

• 10. Jointly decoded “Corynebacterium genome information” with CJ
• 04. Developed genome analysis chip (BAC DNA chip) for the diagnostics of hereditary chromosome aberration disease

• 12. Signed agreement for “Korea – Mongolia disease gene discovery joint research” with the Mongolia’s Ministry of Welfare
• 07. Established MGenBio Co., Ltd, a heteroplastic organ transplant specialist
• 02. Completed construction of high-tech SPF mouse facilities (Gayang-dong, Seoul)

• 11. Zymomonas sequence information listed in NCBI
• 06. Completed the draft of a Korean BAC clone map
• 01. Korea’s first cloned mouse

• 12. Won Bio Technology “Award in 2000 Bioindustry Awards”
• 09. Opened the Life Science Institute and the Bioinformatics Institute
• 08. Decoded the genome of microorganism Zymomonas for the eighth time in the world
• 02. Became the first bio venture company listed on KOSDAQ
• 01. Established the DNA Chip Support Center

• 11. Developed a pilot product for DNA Chip 0.4K
• 11. Launched the KOGEN 100K project
• 06. Obtained venture certification from Small and Medium Business Administration
• 05. Launched Muscular Dystrophy Association (MDA) Korea sponsorship project
• 04. Industry-based technology planning project of the Ministry of Commerce, Industry and Energy

• 12. Chosen by the Military Manpower Administration as an alternative to serving in the military.
• 09. '98 Leading Technology Project (commercialization of a special disease model developed by gene transplant and gene targeting) by the Ministry of Science and Technology
• 06. '98 Venture-Type Small and Medium Business Project (Drug) by the Ministry of Health and Welfare 　1. Developed bioengineering skin anti-aging drug (bioengineering cosmetic additive) using recombinant Hsp70 　2. Developed new substance efficacy search gene transplant mice for new drug development (Hsp70 inductor exploration)
• 05. '98 Industry-based project by the Ministry of Commerce, Industry and Energy (gene transplant mice using cDNA Array – library development)

• 09. Chosen for a leading technology project of “Commercialization of a special disease model developed by gene transplant and gene targeting” by the Ministry of Science and Technology
• 08. Established Disease Model Special Life Resource Bank
• 06. Established Macrogen Inc.